Human vitreous penetration of imipenem. 1994

J P Adenis, and M Mounier, and J L Salomon, and F Denis
Department of Ophthalmology, CHU Dupuytren, Limoges, France.

The purpose of this study was to determine imipenem concentrations in vitreous humor of non-infected human eyes. Ten patients undergoing vitrectomy were infused with a single dose of either 0.5g (5 patients) or 1g (5 patients) of imipenem. Vitreous humor was withdrawn 2 or 4 hours after the end of the infusion. Results differed in relation to the dose. After 0.5g, vitreous levels were stable (approximately 0.20 mg/l), but after 1g they were significantly higher (approximately 2 mg/l). These levels were above the minimum inhibitory concentration of imipenem for 90% (MIC 90) of the main species responsible for endophthalmitis.

UI MeSH Term Description Entries
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D014821 Vitrectomy Removal of the whole or part of the vitreous body in treating endophthalmitis, diabetic retinopathy, retinal detachment, intraocular foreign bodies, and some types of glaucoma. Vitrectomies
D014822 Vitreous Body The transparent, semigelatinous substance that fills the cavity behind the CRYSTALLINE LENS of the EYE and in front of the RETINA. It is contained in a thin hyaloid membrane and forms about four fifths of the optic globe. Vitreous Humor,Bodies, Vitreous,Body, Vitreous,Humor, Vitreous,Humors, Vitreous,Vitreous Bodies,Vitreous Humors
D015378 Imipenem Semisynthetic thienamycin that has a wide spectrum of antibacterial activity against gram-negative and gram-positive aerobic and anaerobic bacteria, including many multiresistant strains. It is stable to beta-lactamases. Clinical studies have demonstrated high efficacy in the treatment of infections of various body systems. Its effectiveness is enhanced when it is administered in combination with CILASTATIN, a renal dipeptidase inhibitor. Imipemide,N-Formimidoylthienamycin,Imipenem Anhydrous,Imipenem, Anhydrous,MK-0787,MK0787,Anhydrous Imipenem,Anhydrous, Imipenem,MK 0787,N Formimidoylthienamycin

Related Publications

J P Adenis, and M Mounier, and J L Salomon, and F Denis
December 1987, American journal of ophthalmology,
J P Adenis, and M Mounier, and J L Salomon, and F Denis
October 1987, The Journal of antimicrobial chemotherapy,
J P Adenis, and M Mounier, and J L Salomon, and F Denis
September 1987, Annals of ophthalmology,
J P Adenis, and M Mounier, and J L Salomon, and F Denis
April 2002, The British journal of ophthalmology,
J P Adenis, and M Mounier, and J L Salomon, and F Denis
December 1986, The Journal of antimicrobial chemotherapy,
J P Adenis, and M Mounier, and J L Salomon, and F Denis
January 1989, Chemotherapy,
J P Adenis, and M Mounier, and J L Salomon, and F Denis
August 1996, Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie,
J P Adenis, and M Mounier, and J L Salomon, and F Denis
April 2008, American journal of ophthalmology,
J P Adenis, and M Mounier, and J L Salomon, and F Denis
July 2009, American journal of ophthalmology,
J P Adenis, and M Mounier, and J L Salomon, and F Denis
October 1999, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics,
Copied contents to your clipboard!